title: Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
abstract: Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.
authors.affiliation: University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. kjs8@pitt.edu
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Smith
authors.forename: Bruce Y
authors.initials: BY
authors.lastname: Lee
authors.forename: Mary Patricia
authors.initials: MP
authors.lastname: Nowalk
authors.forename: Mahlon
authors.initials: M
authors.lastname: Raymund
authors.forename: Richard K
authors.initials: RK
authors.lastname: Zimmerman
mesh_terms: D002487:Centers for Disease Control and Prevention, U.S.; D003362:Cost-Benefit Analysis; D006801:Humans; D007252:Influenza Vaccines / Q000191:economics*; D007251:Influenza, Human / Q000517:prevention & control*; D008390:Markov Chains; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*; D019057:Quality-Adjusted Life Years; D014481:United States; D014611:Vaccination / Q000191:economics*
chemical_list: D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines